The management of cutaneous squamous cell carcinoma (CSCC) is undergoing a notable shift, with systemic immunotherapy playing ...
Immunotherapy—particularly PD-1 inhibition with cemiplimab—is reshaping CSCC care by expanding into neoadjuvant and adjuvant ...
What factors may put patients at an increased risk of cutaneous squamous cell carcinoma, and what should they know about ...
Switching to sirolimus significantly reduces the risk of subsequent cSCC in high-risk kidney transplant recipients with history of the skin cancer. Switching kidney transplant recipients (KTRs) with ...
Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo. The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the ...
Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer, arising from abnormal proliferation of epidermal keratinocytes due to chronic UV exposure. While highly curable (>90%) ...
In an open-label trial of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC), cosibelimab (Unloxcyt), a PD-L1 blocking monoclonal antibody, demonstrated durable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results